Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin

摘要

This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-013-0047-6) contains supplementary material, which is available to authorized users.